MedTrace Logo

The Potential Therapeutic Effect of Melatonin in Gastro-Esophageal Reflux Disease

NCT00915616 · Status: WITHDRAWN · Phase: PHASE3 · Type: INTERVENTIONAL

Last updated 2009-06-08

No results posted yet for this study

Summary

Gastro-Esophageal Reflux Disease was defined as a condition that develops when the reflux of stomach contents causes troublesome symptoms and/or complications. Many drugs used for the treatment of GERD such as omeprazole (a proton pump inhibitor) which is widely used anti-ulcer drug and has been demonstrated to protect against esophageal mucosal injury. Melatonin has been found to protect the gastrointestinal mucosa from oxidative damage caused by reactive oxygen species in different experimental ulcer models. The aim of this study is to evaluate the role of exogenous melatonin in the treatment of reflux disease in human either alone and in combination with omeprazole therapy.

Conditions

  • Gastroesophageal Reflux Disease

Interventions

DRUG

Melatonin

Sponsors & Collaborators

  • Mansoura University

    lead OTHER

Study Design

Purpose
TREATMENT

Eligibility

Min Age
42 Years
Max Age
56 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00915616 on ClinicalTrials.gov